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underlying CVD, frequently starts in childhood with the 
development of inflammatory processes [2].
Inflammation seems to be crucial in the development 
and progression of atherosclerosis from the formation 
of the atheriosclerotic lesion caused by lipid deposition, 
till rupture of fat plaques [3]. During an inflammatory 
reaction, there is the development of an interaction be-
tween the vascular wall, inflammatory cells and plasma 
lipoproteins, with the release of several adhesion mol-
ecules and cytokines. Together with this, acute phase 
markers like fibrinogen, C Reactive Protein (CRP), sial-
ic acid, ceruloplasmin, among others are produced [1]. 
These biomarkers were mentioned in several studies as 
predictors of cardiovascular disease.
Prevention of cardiovascular disorders must be a pri-
ority and all efforts must be done to limit disease pro-
gression or avoid the development of a new CVD. In this 
way, the control of risk factors is a strong weapon in 
CVD prevention.
Cardiovascular risk factors
Most CVDs result from inadequate lifestyle and 
hence from controllable risk factors like smoking, sed-
entarism, excessive weight, bad food diet and stress. 
However, there are also uncontrollable factors that 
contribute to the increased risk of CVD like age, fami-
ly history and gender. Considering gender, last century 
women were more protected against CVDs than men 
due to the cardiovascular protection given by estrogens 
[4]. Nevertheless, nowadays this difference in incidence 
has been decreasing due to habits acquired by women 
like the use of oral contraceptives and tobacco.
Other risk factors that might involve genetic and en-
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Introduction
Nowadays, Cardiovascular Disorder (CVD) is a health 
problem with big relevance and concern, being associ-
ated with numerous risk factors [1]. For this reason, it is 
considered one of the most common causes of mortal-
ity and morbidity in developed countries. Usually, indi-
viduals with CVD only become symptomatic when they 
reach adult age, however atherosclerosis, the process 
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to endothelium is activated by adhesion molecules like 
Selectins (selectin-E, selectin-P), cellular adhesion mol-
ecules (Inter-Cellular Adhesion Molecule-1 (ICAM-1), 
Vascular Adhesion Molecule-1 (VCAM-1)) and integrins. 
Chemotaxis and monocytes entrance to the sub-endo-
thelial space is promoted by a Protein (protein-1) that 
potentiates attraction of monocytes, Interleukin-8 (IL-
8), and one chemokine, called fractalkine. After that, 
monocytes and macrophages start to differentiate. 
Macrophages receive oxidised LDL via scavenger re-
ceptor (CD36, scavenger receptor-A), becoming sponge 
cells, lesion indicators [1]. Later, smooth muscle cells 
migrate into the intima, proliferate and forma fibrous 
matrix, that keeps on growing, narrowing the artery.
It is believed that, during the processes of necrosis 
and apoptosis, lipid filled macrophages release matrix 
metalloproteinases, that damage the endothelium. 
Since LDL filled macrophages are enriched in tissue fac-
tor, this one is released from the macrophage and con-
tacts circulating platelets, resulting in the formation of 
thrombi and consequent acute coronary syndromes [1].
C Reactive Protein (CRP)
Characterization and structure
CRP was first described by Tillet and Francis, more 
than 70 years ago, during a study in patients having 
infection with Streptococcus pneumoniae. Serum ob-
tained from these patients, during the acute phase of 
symptoms, included a substance capable of precipitat-
ing the C polysaccharide of the cell wall of pneumococ-
cus. This substance was called C reactive. Several stud-
ies showed that this protein is undetectable in healthy 
patients, however reaches very high levels in patients 
having infections. After patient’s recovery, levels of this 
protein become undetectable again [18].
CRP is a member of the family of proteins called 
pentraxins and has a molecular weight of 115135 Da. 
This protein is formed by five identical non-glycosylated 
polypeptide chains (23027 Da) of 206 aminoacids each. 
The semonomers are linked in a non-covalent fashion, 
organized in a very stable discoid structure with resis-
tance to proteolysis [19]. Each monomer has two dis-
tinct faces, the recognition/binding face and the effec-
tor face. The binding face, to which two calcium ions 
are associated, recognises the phosphocholine residues 
of the C polysaccharide of Streptococcus pneumoniae 
[20,21], and the effector face has affinity for the com-
plement factor 1q and FcγRs [20].
Metabolism/Synthesis of CRP
CRP is an acute phase protein produced in liver due 
to stimulation by several pro-inflammatory cytokines 
derived from monocytes/macrophages or adipose tis-
sue [11,22]. Its liver production is mainly stimulated 
by IL-6, being this synthesis synergically increased by 
IL-1 [18,23]. It is consensus that pro-inflammatory risk 
vironmental causes are high levels of plasma glucose, 
since insulin resistance leads to dyslipidemias [5] and in-
creased blood cholesterol levels in the form of LDL (that 
has higher chance of oxidation and deposition in blood 
vessels).
Still other CVD risk factors that seem to involve pure 
genetic causes are high plasma levels of lipoprotein (a) 
[6], hyperhomocysteinemia [7,8], as well as high levels 
of C Reactive Protein (CRP) in blood [9].
As mentioned, during the inflammation process 
there is an increase in acute phase biomarkers like CRP. 
For this reason, this proteinis of special interest since its 
plasma concentration is easily quantified, it has the best 
clinical-epidemiological correlation and, in opposition 
to other acute phase markers, it shows relatively stable 
plasma levels, allowing its correct quantification [10]. 
Besides these findings, this protein shows characteris-
tics that make it very attractive [11]. In the first place, 
it is an acute phase protein, being an unspecific marker 
of systemic inflammation [12], whose serum levels in-
crease as a response to several types of lesion, partic-
ularly bacterial infections that constitute inflammatory 
stimuli. Secondly, its hepatic production is mainly stim-
ulated by Interleukin 6 (IL-6) [11]. At the beginning of an 
inflammatory process, there is an increase in CRP levels 
in the first eight hours that can reach 300 mg/dL in 48 
hours [13]. C reactive protein is an independent risk fac-
tor for CVDs [10].
Growing evidences suggest that hs-CRP constitutes 
an important cardiovascular risk marker and is phys-
io-pathologically associated with the atherosclerotic 
process, having value in primary and secondary preven-
tion [11]. However, its serum concentrations can be in-
fluenced by other factors like pharmaceutical products, 
hormones and tobacco [12].
Atherosclerosis
Atherosclerosis starts with systemic mediators that 
have a key role in its progression, as well as in its stabili-
ty and plaque rupture. The association between inflam-
matory biomarkers, the atherosclerotic phase and the 
dynamic of cardiovascular events related to atheroscle-
rosis seems to be fundamental for CVD development 
[14]. Chronic inflammation of blood vessels seems to be 
the main cause of atherosclerotic plaque formation and 
its rupture [15]. Plaque formation results from accumu-
lation of lipids, inflammatory cells and fibrotic elements, 
that deposit in the wall of arteries and blood vessels, 
leading to their obstruction [16].
The inflammatory process initiates with the increase 
of endothelium permeability to inflammatory cells, giv-
ing rise to oxidized LDL deposition [17]. After endotheli-
um dysfunction, mononuclear cells like monocytes and 
T lymphocytes adhere firmly to the endothelium and 
migrate to involving tissues (sub-endothelial space) by a 
process called diapedesis. The attachment of leucocytes 
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Between all existing markers, CRP shows up due to 
its high sensitivity in evaluating inflammatory states, 
showing a strong increase as a response to several in-
flammatory and infectious stimuli. Measurement of CRP 
plasma levels helps the clinical evaluation of the pres-
ence, extension and activity of the inflammatory pro-
cess and the follow-up of the evolution and therapeutic 
response [28].
CRP detection and development of atherosclero-
sis
In the beginning, CRP plasma levels were determined 
by serum-agglutination performed in latex particles in a 
slide. This assay allowed a semi-quantitative determi-
nation, with a subjective interpretation. Later, quanti-
tative methods for CRP quantification were developed 
through immunoturbidimetry and nephelometry [32].
Due to the low sensitivity of these methods on de-
tection of low levels of inflammation, in the 90s a high 
sensitivity nephelometry method for detection of very 
low levels of serum CRP was developed, called high sen-
sitivity CRP (hs-CRP). This is the ideal laboratory meth-
od in use to determine cardiovascular risk linked with 
chronic systemic vascular inflammation of atherosclero-
sis, having a detection limit of 0.3 mg/L [11].
Table 1 describes the relationship between hs-CRP 
plasma concentrations and the risk factor, or capacity of 
cardiovascular events prediction.
Several studies confirm that hs-CRP predicts cardio-
vascular events in healthy women [33] and men [34], in 
individuals with traditional risk factors [35] or with CVD 
[23]. The capacity of hs-CRP to predict CVD risk is in-
dependent from traditional risk factors [34,36]. hs-CRP 
is an additional risk factor for coronary artery disease 
when associated with high plasma levels of cholesterol 
[22,37].
For many years, CRP was used as a complementary 
method for diagnosis of inflammatory processes of any 
nature. Meanwhile, with the discovery of inflammatory 
components involved in cardiovascular events, mainly 
atherosclerosis, CRP was assigned as a risk indicator for 
coronary disease and cerebral vascular accidents [28], 
being an inflammatory marker considered strong pre-
dictor, that is independent of the risk for cardiovascular 
event or death.
Several prospective clinical studies have shown that 
CRP is associated with mortality risk in short or long 
term both in patients having acute or chronic ischemic 
factors like oxidized LDL and infectious agents such as 
Chlamydia pneumoniae trigger a pro-inflammatory re-
sponse [24]. This response leads to the increase in IL-
1β and TNF-α secretion, that consequently provokes 
release of cytokine IL-6. More over, IL-6, after binding 
to its receptor in liver, leads to secretion and release of 
CRP and amyloid A serum protein [22].
Besides liver production, data suggests that CRP is 
also produced in the atherosclerotic lesion (specially in 
smooth muscle and macrophages), in kidneys, neurons 
and alveolar macrophages [25,26]. Moreover, there are 
evidences of stimulation of CRP production by lipid per-
oxidation and infection by cytomegalovirus that triggers 
a cascade of pro-inflammatory cytokines [3].
Work of Chang, et al. [27] showed that CRP does not 
bind to native LDL. Instead, the increase in reactive ox-
ygen production leads to oxidation of LDL that triggers 
entrance of LDL in macrophages mediated by CRP. CRP 
binds to oxidized phosphatidylcholine present at the 
surface of LDL [27].
Healthy individuals have low plasma levels of CRP 
(< 0.5 mg/dL). However, during inflammatory process-
es, serum concentration of this protein can rise one 
hundred to one thousand times. Its synthesis starts 4-6 
hours after stimulation, duplicates every 8 hours and 
reaches a maximum after 50 hours (around 2 days). Its 
levels can reach 300 mg/dL in 48 hours. These charac-
teristics make CRP a relevant clinical marker due to its 
stability, high sensitivity, good reproductivity and preci-
sion. This protein has a plasma half-life of 19 hours even 
after stimulus, trauma or surgery. It can take several 
days until it reaches basal levels [28,29]. In the absence 
of chronic stimulus, CRP levels normalize in 3-4 days. 
On the other hand, in chronic inflammatory states, CRP 
concentrations can remain high forever [28].
It has also been observed a correlation between CRP 
genetic variants and its plasma levels. Michopoulos, 
et al. [30] saw increased CRP plasma levels associated 
with the presence of the rs1130864 CRP polymorphism. 
Moreover, Markt, et al. [31] detected mean CRP levels 
significantly elevated in men with one copy of the vari-
ant alleles rs3093075 and rs1417938 compared to those 
with no copies. On the other hand, the same study ob-
served that men with one copy of the variant allele 
rs1800947 had significantly lower mean CRP levels. The 
rs2808630 polymorphism was not associated with cir-
culating CRP [31].
CRP plasma concentration differs between individu-
als. Each person has its own basal level that remains sta-
ble over the years without big changes during the day or 
season. Diet does not interfere with CRP levels as well. 
However, these values tend to increase slightly with age 
in healthy individuals, probably due to the development 
of diseases still in the sub-clinical stages [29].
Table 1: Risk degree in the development of cardiovascular 
problems related to serum levels of hs-CRP [1].
Risk degree hs-CRP concentration (mg/L)
Low risk < 1
Intermediate risk 1-3
High risk > 3
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Nitric oxide produced by endothelial cells has an es-
sential role in blood vessels relaxation, being strategical-
ly linked to the endothelial cell membrane. Moreover, 
NO contradicts vascular smooth muscle contraction and 
inhibits platelet activation. It also acts on integrins, by 
modifying leucocyte adhesion and neutrophil diape-
deses [44]. NO is continuously released from vascular 
endothelium, being responsible for the maintenance of 
tissues blood flow and for tissue extravasation control 
[45].
Therefore, all described processes are limited when 
CRP plasma levels are high [29]. By inhibiting NO pro-
duction, CRP contributes to apoptosis of endothelial 
cells and consequently to pro-atherogenic and pro-in-
flammatory events (Figure 1) [46].
Additionally, CRP not only controls the expression of 
adhesion molecules, like ICAM-1 and VCAM-1, through 
chemokine MCP-1, but also facilitates entrance of LDL, 
by opsonization, in macrophages [29,47]. Moreover, it 
has the power to induce oxidation of that cholesterol, 
contributing for the development of atherosclerosis. 
CRP is also involved in destabilization of atheroma fi-
brous layer, by stimulating Matrix Methaloproteinase-1 
(MMP-1), released with collagen and proteins degrada-
tion. This destabilization occurs equally by the decrease 
in concentration of Plasminogen Activator (tPA), respon-
sible for clot lysis in vascular wall, and for the increase 
in the level of Plasminogen Activator Inhibitor (PAI-1), 
that inhibits fibrinolysis. This process facilitates thrombi 
formation in endothelial wall, increasing the risk of car-
diovascular events [48,49] (Figure 2).
Therefore, CRP is not only an inflammatory marker 
of atherosclerosis and coronary events, but also a CVD 
cardiac disease, or in individuals with atherosclerosis 
risk [38]. In 2003, Ishikawa, et al. [39] concluded that 
CRP is located inside the atherosclerotic plaque, having 
an important role in plaque vulnerability. In the same 
way Inoue, et al. [24] in 2005, showed that CRP is pro-
duced in the atherosclerotic plaque responsible for 
acute coronary syndrome, demonstrating the existence 
of a CRP gradient in coronary arterial circulation close 
and far away from the plaque.
CRP as risk factor
Evidences suggest that CRP is not only an inflamma-
tory marker, but also participates actively in the ath-
erosclerosis process [40]. Its levels correlate directly 
with several cardiovascular risk factors, like body mass 
index, smoking, systolic arterial pressure, serum levels 
of triglycerides and total cholesterol, cardiac frequency, 
fasting glycaemia and cardiovascular disease or stroke 
history and in an inverse way with HDL levels, both in 
children and in adults [41,42].
By its interaction with classic risk factors, CRP can 
lead to changes in the pro-atherosclerotic profile of pa-
tients [43]. This protein has direct influence in athero-
sclerotic vessels through the activation of the comple-
ment system, closely related with the initial stages of 
atherosclerotic plaque formation, and with the stimulus 
of tissue factor synthesis by monocytes (procoagulant 
effect), and consequently, in promotion of inflamma-
tion and thrombosis [10].
CRP favours the development of a pro-inflammatory 
state, through reduction of endothelial Nitric Oxide Syn-
thase Activity (eNOS) [29], as well as reduction of tran-
scription of eNOS coding genein endothelial cells [29].
 
↑ IL-6 
↑ CRP        
↑Plasminogen activator inhibitor 
↓Plasminogen activator 
↓eNOS 
↑ Adhesion molecules   ↓Fibrinolysis 
↑ Cardiovascular 
events 
Figure 1: Cascade of changes induced by CRP that lead to cardiovascular events [46].
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Described data show that the use of statins in prima-
ry prevention of CVD leads to a decrease in CVD mortal-
ity. It was also seen the decrease of coronary events in 
groups with different characteristics of the population 
under study [54].
According with guidelines concerning “Emerging bio-
markers for primary prevention of cardiovascular dis-
ease” from the National Academy of Clinical Biochem-
istry Laboratory [55], hs-CRP cannot be determined 
in general population to evaluate cardiovascular risk. 
However, it can be used to stratify cardiovascular risk in 
adults with intermediate risk of coronary disease, and 
can help the decision about statins use in primary pre-
vention [11].
CRP in secondary prevention
The objectives of secondary prevention are focused 
in avoiding a new cardiovascular event and identify 
the progression of myocardium dysfunction, leading 
to a reduction of mortality rate due to these diseases. 
To achieve these goals, secondary prevention includes 
changes in lifestyle and continuous use of medicines 
[56].
For hypertensive patients it is essential smoking ces-
sation, weight loss, decrease of cholesterol serum levels 
and practice of physical exercise. Moreover, the con-
tinuous use of aspirin, β-blockers, inhibitors of the an-
giotensin I conversion enzyme, and in women in meno-
pause, hormone replacement are also essential [56].
Several studies have shown the value of CRP in sec-
ondary prevention of CVDs. The FRISC study [57] per-
formed in 917 patients with acute coronary syndrome 
showed that hs-CRP has independent capacity of car-
diovascular mortality prediction. Another randomized 
prospective study in 391 patients having non-fatal/fatal 
acute myocardial infarction (CARE study [36]), proved 
that the use of pravastatin leads to risk reduction of cor-
mediator due to its contribution for the lesion process, 
for plaque break and incoronary thrombosis mecha-
nisms [29,46]. However, more research is needed to be 
able to conclude about the effects of CRP as a risk factor 
of CVD and its clinical relevance [47].
CRP in primary prevention
Due to the relationship between high CRP plasma 
levels and cardiovascular mortality and morbidity risk 
[11], it is important to establish a primary care line to 
decrease CVDs. For this, it is essential the evaluation of 
cardiovascular risk factors to stop their progression.
Several prospective studies having CRP as central 
target, have shown the benefits of primary prevention. 
In 1999, the MONICA-Augsburg study [50] performed in 
a sample of 936 asymptomatic men, concluded that the 
increase of hs-CRP leads to a 19% increased risk of fatal 
and non-fatal coronary events.
In the same way, the PREVEND study in 8139 as-
ymptomatic men and women observed a relationship 
between hs-CRP and angiographic characteristics and 
consequently clinical instability of the atherosclerotic 
plaque [51]. The use of lovastatin in the treatment of 
5742 individuals (AFCAPS/TexCAPS study) reduced the 
occurrence of the first coronary event both in individu-
als with high cholesterol levels, and in the ones having 
high hs-CRP levels, even with low lipid profile [52].
The PRINCE study [53] performed with 1702 asymp-
tomatic men and women showed that pravastatin re-
duces hs-CRP levels in individuals without previous his-
tory of CVD, independently of cholesterol levels.
Rosuvastatin was tested in 1802 asymptomatic men 
and women (having cholesterol LDL < 130 mg/dL and 
hs-CRP > 2 mg/L) in the JUPITER study [54]. It was ob-
served a reduction of 50% in LDL levels and 37% in hs-
CRP levels, consequently reducing cardiovascular events 
in these apparently healthy individuals.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inflammatory cellsin vascular wall and pro-
inflammatory cytokines 
CRP 
Liver 
Endothelial cell 
Monocyte/macrophage 
Smoothmusclecell 
Stimulates prolife ration and migration of smooth muscle cells 
Increase of free radicals 
 
↓ NO release 
↑ Expression of ICAM-I and VCAM-1 
↑ PAI-1 
↑ Entrance of LDL-cholesterol 
↑ Expression of cytokines (IL-6, TNF and IL-1) 
↑ Expression of tecidular factor 
↑ PAI-1 
Figure 2: CRP role in stimulation of endothelial cells, mononuclear cells (monocytes and macrophages) and smooth muscle 
cells leading to the production of inflammatory mediators [49].
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and collaborators [34] published the first study that 
demonstrated the effect on reduction of cardiovascular 
events, because of therapy with acetylsalicylic acid, to-
gether with serum CRP levels reduction [34]. This study 
showed that a dose of aspirin per day contributes to 
a 44% decrease in myocardial infarction risk. Patients 
having higher CRP levels showed higher risk decrease 
[34]. In the same way, a 75 mg per day dosage during 
a month led to a meaningful reduction in plasma CRP 
[61]. On the other hand, other studies demonstrated 
the ineffectiveness of aspirin relative to CRP levels [62]. 
Cyclooxygenase-2 Inhibitors (COX-2) (rofecoxib, cele-
coxib) were also tested for their ability to reduce CRP 
levels. Some studies observed a decrease on serum CRP 
levels, when used alone or in combination with statins 
or aspirin [63,64].
In the same way, Lincoff, et al. [65] tested the effect 
of clopidogrel, an antiplatelet agent, on CRP levels and 
observed a 32% reduction [65].
Besides the anti-inflammatory effects on atheroscle-
rotic tissues, statins also lead to reduction in CRP lev-
els [53]. Riesen, et al. [66] observed beneficial effects 
on plasma CRP reduction. In this study, it was observed 
that therapy with high dosage of statins or its combi-
nation with COX-2 inhibitors, given before an invasive 
coronary procedure in patients with unstable angina, 
rapidly decreased CRP serum levels [66].
There are, in fact, numerous studies showing the 
power of statins in reducing hs-CRP levels, that ob-
served a reduction of 13 to 50% in its plasma levels [67-
70]. This was observed in patients with obesity [68], di-
abetes [70], dyslipidemias [67,68] and coronary artery 
disease [69]. This statin associated with hs-CRP levels 
reduction results in a bigger clinical benefit in the treat-
ment of patients having atrial fibrillation [71].
Another lipid lowering agent, ezetimibe, an inhibitor 
of cholesterol absorption, was tested in combination 
with statins [67]. This study observed a 41% reduction in 
CRP plasma levels when using the combined treatment 
onary events, mainly in individuals with inflammation 
evidence determined by hs-CRP, not related with lipid 
levels.
Intensive therapy with a statin applied to 3745 pa-
tients with acute coronary syndrome (PROVE-IT study 
[58]) could reduce hs-CRP levels below 2 mg/L, conse-
quently decreasing the risk of acute myocardial infarc-
tion or fatal coronary events, independently on the re-
duction of LDL levels.
The PEACE study [59] (with 3771 individuals having-
stable coronary disease) allowed to associate plasma 
hs-CRP levels above 1 mg/L, to higher mortality risk due 
to cardiovascular disease, acute myocardial infarction 
or stroke.
Since the inflammatory process is an integral part of 
atherosclerosis evolution, the use of a biomarker like 
CRP, becomes quite useful in combination with the con-
trol of classic risk factors like lipid levels, change of eat-
ing habits, weight loss associated with regular physical 
activity, control of glycaemic levels and smoking cessa-
tion. The interconnection of these factors are strategies 
for reduction of cardiovascular events in primary and 
secondary prevention [29,47].
Therapy for high levels of CRP
Knowing that CRP is involved in CVD pathophysiolo-
gy, it is expected that reduction of CRP levels prevents 
the development of the disorder and its complications. 
Data suggests that certain drugs can reduce CRP levels, 
however, the clinical relevance of these interventions is 
not known [60].
Prevention of cardiovascular events in individuals 
with high CRP levels can be achieved using CRP lowering 
agents. Table 2 summarizes the main studied agents/
strategies that contribute to reduction of plasma CRP.
Aspirin has the capacity of reducing the risk offu-
ture cardiovascular events due to its antiplatelet and 
anti-inflammatory properties [47,60]. In 1997, Ridker 
Table 2: CRP lowering agents.
Agent Examples of studies
Antiinflammatory drugs (aspirin) [34,61]
Cyclooxygenase inhibitors (rofecoxib; celecoxib) [63,64]
Antiplatelet agents (clopidogrel) [65]
Lipid lowering agents (statins) [66-71]
Lipid lowering agents (Inhibitor of cholesterol absorption - ezetimibe) [67]
Lipid lowering agents (fenofibrate) [72,73]
Lipid lowering agents (niacin) [74,75]
Antidiabetic agents (thiazolidinedione derivatives) [76,77]
Β-adrenoreceptor antagonists [78-81]
Antioxidants (vitamin E) [82-85]
Inhibitors of renin-angiotensin system (ACE; angiotensin II receptor blockers) [87,88]
Calcium channel antagonists [89]
Curcuminoids [90]
Lipid lowering agents (lipid lowering diet) [91]
Regular physical exercise [92-98]
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sedentary adults. This studydid not show significative 
reductions of CRP and IL-6 after aerobic training, how-
ever, reductions of CRP plasma levels were observed in 
response to resistance training [98]. Smith and co-work-
ers [99] have shown that long term physical exercise 
can strongly reduce plasma levels of inflammatory cy-
tokines and CRP. This anti-inflammatory effect demon-
strates the benefits of physical activity in cardiovascular 
disease prevention [99].
Shortcomes on the use of CRP
As mentioned previously, CRP has a long half-life 
(around 19 hours), reaching its basal levels after several 
days. Indeed, the prognostic value and the evolution of 
the treatment in an initial phase might not be the most 
correct, making it a limitation on its use. Moreover, CRP 
takes 4-6 hours to be produced, after stimulus. So, its 
detection might not be fast enough to detect a cardio-
vascular event [28].
CRP is an unspecific marker of acute phase response 
and increases of its plasma levels are expected not only 
in inflammation, but also in other clinical situations like 
infection and necrosis [100,101]. In this way, it is im-
portant to say that CRP like any other marker, cannot be 
used alone in diagnosis or monitorization of therapeutic 
response.
Conclusion
CVDs are the main cause of incapacity and prema-
ture death in the whole world. In these circulatory dis-
eases, atherosclerosis is the basis for their progression. 
However, CVD development does not depend on one 
factor alone, but on the association of several risk fac-
tors, resulting in a synergetic and multiplicative effect. 
With the high prevalence of risk factors for CVD in the 
general population, it becomes essential to give special 
attention to their prevention, detection and correction.
CVD prevention should start during childhood and 
adolescence with the adoption of healthy habits, since 
these will be used in adult life. Risk of CVD development 
can be detected using biomarkers that have been rele-
vant in diagnosis, prognosis and as a therapeutic guide 
for these disorders. Biomarkers constitute a biologi-
cal-qualitative and quantitative parameter of physiolog-
ical changes or pathological processes.
Among biomarkers, CRP, an inflammatory marker, is 
considered to have bigger clinical relevanceand higher 
additional prognostic information, being independent 
of traditional risk factors. Moreover, CRP is an inflam-
matory mediator in cardiovascular events.
CRP production, together with the increase of other 
pro-inflammatory cytokines starts during the first stage 
of the inflammatory process. This shows its role as a risk 
marker in this process. Moreover, CRP leads to instabil-
ity of vascular endothelium by reducing NO production, 
induces LDL oxidation by facilitating LDL entrance in the 
[67]. Fenofibrate, usually used in the treatment of hy-
pertriglyceridemia also led to CRP reduction, being ob-
served a decrease between 74-84% [72,73]. In the same 
way, treatment of dyslipidemias with a combination of 
niacin/statin, allowed a 24% reduction of CRP [74,75]. 
The effect of niacin alone was not tested in these stud-
ies.
Some antidiabetic agents can also have beneficial 
effects on CRP levels. A 40% reduction of CRP levels, 
after treatment with thiazolidinedione derivatives, was 
observed in type 2 diabetes mellitus patients [76] and 
in nondiabetic hypertensive patients [77]. Moreover, 
β-adrenoreceptor antagonists, normally use in the 
treatment of hypertension and coronary artery disease, 
led to reduction of CRP levels ranging between 36-73%, 
depending on the type of antagonist used [78-81].
The use of antioxidants has also been shown to con-
tribute to CRP reduction. Several studies observed de-
creased plasma CRP levels when using vitamin E, rang-
ing from 49 to 81% [82-85], but no effect was seen by 
vitamin C [86].
Another group of drugs known to have effect on CRP 
plasma levels are the inhibitors of Renin-Angiotensin 
system. Angiotensin converting enzyme inhibitors and 
angiotensin II receptor blockers were tested and both 
led to decrease in CRP levels [87,88].
Some calcium channel antagonists can also lead to 
plasma CRP reduction. This was observed in the study 
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macrophage, and is involved in destabilization of the fi-
brous layer of the atheroma. This destabilization occurs 
through the stimulus of matrix methaloproteinase-1, 
released with collagen and other proteins degradation, 
inducing thrombus formation in the endothelial wall 
and consequently increasing the risk of cardiovascular 
events.
So, CRP measured by high sensitivity methods in in-
dividuals having apparent cardiovascular risk, should be 
seen not only as an inflammation marker but also as a 
possible risk factor for CVDs.
High CRP levels can be reduced by the use of several 
strategies that go from changes in daily habits to the use 
of several drugs that directly interfere with CRP serum 
concentration.
In conclusion, the prevalence of high risk individuals 
for the progression of CVD, points out for the need of 
strategies with coordinate intervention of several health 
experts. These strategies should involve prevention, de-
tection and effective treatment of cardiovascular risk 
factors, contributing in this way to the risk reduction in 
the population.
It is important the adoption of measures in the pop-
ulation, that potentiate the reduction of the risk of de-
veloping this type of disorders, the application of a fast 
and adequate treatment and the use of secondary pre-
vention measures that will reduce their return.
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